Epidermolysis bullosa and inherited blistering disorders

Overview & Definition

A baby born with skin that shears away at the lightest touch is the face of epidermolysis bullosa, a group of inherited mechanobullous disorders in which mutations in the structural proteins that hold the skin together leave it too fragile to withstand ordinary friction or minor trauma. Where a healthy child shrugs off a knock or a tight shoe, a child with EB blisters, erodes and sometimes scars. The blistering is mechanical rather than inflammatory: it appears where the skin is rubbed, and it can affect the mucous membranes, nails, hair, teeth, eyes and airway as readily as the skin. [9]

The unifying defect is a loss of adhesion somewhere along the epidermis-to-dermis axis. The keratinocytes of the basal layer, the basement membrane zone, and the anchoring fibrils that tether it to the dermis form a chain, and a weakness at any one link produces a distinct disease with its own severity, complications and prognosis. This is why EB is classified not by its clinical appearance alone but by the ultrastructural level at which the skin splits, because that split localises the defective protein and predicts the course. [1]

EB is a lifelong, multisystem condition rather than a purely dermatological one. Severe subtypes cause chronic wound pain, growth failure and anaemia, oesophageal and airway disease, limb deformity, and a markedly increased risk of aggressive skin cancer, so care is built around a multidisciplinary team rather than a single clinician. No therapy reverses the genetic defect in most patients, but atraumatic wound care, pain control, nutrition, surgery, surveillance and, for some, gene therapy transform outcome and quality of life. [11]

References12Show ledgerHide ledger

1. [1]Fine JD, Bruckner-Tuderman L, Eady RA Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol, 2014.PMID 24690439
2. [2]Has C, Bauer JW, Bodemer C Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol, 2020.PMID 32017015
3. [3]Guide SV, Gonzalez ME, Bağcı IS Trial of Beremagene Geperpavec (B-VEC) for Dystrophic Epidermolysis Bullosa. N Engl J Med, 2022.PMID 36516090
4. [4]Marinkovich MP, Paller AS, Guide SV Long-Term Safety and Tolerability of Beremagene Geperpavec-svdt (B-VEC) in an Open-Label Extension Study of Patients with Dystrophic Epidermolysis Bullosa. Am J Clin Dermatol, 2025.PMID 40220208
5. [5]Mariath LM, Santin JT, Schuler-Faccini L Inherited epidermolysis bullosa: update on the clinical and genetic aspects. An Bras Dermatol, 2020.PMID 32732072
6. [6]Chandrasekaran A, Moser JC Cutaneous Squamous Cell Carcinoma in Epidermolysis Bullosa: A Review of Pathogenesis, Diagnosis and Management. Cancers, 2025.PMID 41097738
7. [7]Marwah MK, Kaur K, Ahmad S Innovations in topical epidermolysis bullosa treatment: integrating advanced dressings, bioactive therapies and tissue-engineered skin. Daru, 2026.PMID 41931158
8. [8]Andreou S, Sarsam S, Murrell DF Understanding the efficacy and tolerability of topical therapies for epidermolysis bullosa. Expert Rev Clin Pharmacol, 2026.PMID 41772988
9. [9]Fine JD Inherited epidermolysis bullosa. Orphanet J Rare Dis, 2010.PMID 20507631
10. [10]Fine JD, Johnson LB, Weiner M Epidermolysis bullosa and the risk of life-threatening cancers: the National EB Registry experience, 1986-2006. J Am Acad Dermatol, 2009.PMID 19026465
11. [11]El Hachem M, Diociaiuti A, Bonamonte D Taking care of patients with recessive dystrophic epidermolysis bullosa from birth to adulthood: a multidisciplinary Italian Delphi consensus. Orphanet J Rare Dis, 2025.PMID 40091088
12. [12]Rechichi J, De Rose DU, Pugnaloni F Use of Tramadol in Pain Management of Neonates with Epidermolysis Bullosa: A Single-Center Experience. Children (Basel), 2026.PMID 42353915